| Literature DB >> 31925647 |
Michele Porcu1, Cinzia Solinas2, Cristina Migali3, Angelo Battaglia2, Marina Schena2, Lorenzo Mannelli4, Alfredo Addeo5, Karen Willard-Gallo6, Luca Saba7.
Abstract
The immunotherapy revolution in cancer treatment involves a variety of specialists, not only oncologists, but also internal medicine physicians, endocrinologists, dermatologists, gastroenterologists, rheumatologists, and radiologists, introducing new scenarios and novel challenges in the diagnosis and management of a number of novel immune-related adverse events. Among these, immune checkpoint inhibitor-induced pancreatic injury has been described (occurring in up to 4% of patients) and has been reported to be responsible for visits to the emergency departments in up to 1.9% of patients treated with immune checkpoint inhibitors. This side effect can be symptomatic or non-symptomatic, and can be associated with the development of long-term damage to the pancreas, requiring the involvement of different specialists, including radiologists and gastroenterologists in the multidisciplinary team that manages these patients. The aim of this narrative review is to provide a summary of the available literature related to immune checkpoint inhibitor-induced pancreatic injury including the epidemiology, the clinical findings, and the management algorithm for diagnosis with a detailed analysis of the differential diagnosis at imaging, and treatment. A more in-depth focus is dedicated to symptomatic acute pancreatitis with its peculiar findings at imaging (ultrasound, computed tomography, and magnetic resonance imaging).Entities:
Mesh:
Substances:
Year: 2020 PMID: 31925647 DOI: 10.1007/s11523-019-00694-w
Source DB: PubMed Journal: Target Oncol ISSN: 1776-2596 Impact factor: 4.864